5AM Venture Management, LLC

In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), 5AM Venture Management, LLC reported 29 stock positions worth $260.1 million. Its top holding was Skye Bioscience (SKYE) at 15.9% of the portfolio, followed by Entrada Therapeutics (TRDA, 11.1%) and Dianthus Therapeutics (DNTH, 7.1%). Compared with Q1 2025, it sold out of 2 and reduced 3. The biggest sale was Entrada Therapeutics (TRDA, shares −2%).

Most Recent 13F
Q2 2026
Location
SAN FRANCISCO, CA
CIK
0001799883
Portfolio Value
$260.1M (Q2 2025)
SEC Filing
0001085146-25-005241 ↗ filed Aug 14, 2025

Holdings Value

0$100.0M$200.0M$300.0M$400.0M$500.0M Q1 2024: $446.6M Q1 2024 Q2 2024: $447.1M Q2 2024 Q3 2024: $484.0M Q3 2024 Q4 2024: $419.1M Q4 2024 Q1 2025: $264.4M Q1 2025 Q2 2025: $260.1M $260.1M Q2 2025 Q3 2025: $273.0M Q3 2025 Q4 2025: $318.1M Q4 2025 Q1 2026: $360.2M Q1 2026 Q2 2026: $287.9M Q2 2026

Holdings 29 stocks · $260.1M
SKYE Skye Bioscience Inc. 15.93% 9,913,168 $41.4M No change
TRDA Entrada Therapeutics Inc. 11.13% 4,308,379 $29.0M Reduce -2.3%
DNTH Dianthus Therapeutics Inc. 7.05% 984,725 $18.3M Reduce -4.2%
ELVN Enliven Therapeutics Inc. 5.96% 772,477 $15.5M Reduce -41.6%
PHVS Pharvaris NV 5.40% 797,600 $14.0M No change
MLTX Moonlake Immunotherapeutics 5.12% 282,313 $13.3M No change
CNTA Centessa Pharmaceuticals Ltd. 4.20% 830,945 $10.9M No change
VOR Vor Biopharma Inc. 3.96% 6,361,723 $10.3M No change
VRDN Viridian Therapeutics Inc. 3.96% 736,595 $10.3M No change
TECX Tectonic Therapeutic Inc. 3.91% 511,660 $10.2M No change
CLDX Celldex Therapeutics Inc. 3.89% 497,270 $10.1M No change
EYPT Eyepoint Inc. 3.80% 1,050,000 $9.9M No change
TYRA Tyra Biosciences Inc. 3.46% 939,298 $9.0M No change
PRAX Praxis Precision Medicines I 2.75% 170,000 $7.1M No change
GHRS GH Research PLC 2.68% 572,665 $7.0M No change
ERAS Erasca Inc. 2.64% 5,405,404 $6.9M No change
BHVN Biohaven Ltd. 2.60% 478,972 $6.8M No change
VKTX Viking Therapeutics Inc. 1.93% 189,593 $5.0M No change
SCPH Scpharmaceuticals Inc. 1.76% 1,200,647 $4.6M No change
CAMP CAMP4 Therapeutics Corp. 1.63% 2,927,915 $4.2M No change
ARTV Artiva Biotherapeutics Inc. 1.37% 2,353,304 $3.6M No change
SRZN Surrozen Inc. 1.07% 310,000 $2.8M No change
SLN Silence Therapeutics PLC-ADR 1.06% 476,200 $2.8M No change
TARA Protara Therapeutic Inc. 0.93% 800,000 $2.4M No change
ALEC Alector Inc. 0.54% 995,841 $1.4M No change
RLYB Rallybio Corp. 0.47% 3,630,724 $1.2M No change
ADVM Adverum Biotechnologies Inc. 0.45% 541,666 $1.2M No change
ZNTL Zentalis Pharmaceuticals Inc. 0.22% 490,000 $568K No change
MERSANA THERAPEUTICS INC 0.15% 1,305,000 $386K No change

Portfolio Sells Q1 2025 → Q2 2025
TRDA Entrada Therapeutics Inc. Reduce -2.3% 11.13% −3.94
ELVN Enliven Therapeutics Inc. Reduce -41.6% 5.96% −3.89
ANAB Anaptysbio Inc. Sold out 0.00% −2.52
CDTX Cidara Therapeutics Inc. Sold out 0.00% −0.46
DNTH Dianthus Therapeutics Inc. Reduce -4.2% 7.05% +0.00

Portfolio Buys Q1 2025 → Q2 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 16$287.9MMPLT, TYRA, TRDA, PHVS, CAMP
Q1 2026 20$360.2MERAS, TRDA, TYRA, CAMP, CNTA
Q4 2025 21$318.1MTRDA, CAMP, TYRA, VRDN, PHVS
Q3 2025 25$273.0MSKYE, TRDA, PHVS, CAMP, CNTA
Q2 2025 29$260.1MSKYE, TRDA, DNTH, ELVN, PHVS
Q1 2025 31$264.4MTRDA, ELVN, DNTH, SKYE, PHVS
Q4 2024 31$419.1MTRDA, ELVN, SKYE, TECX, ARTV
Q3 2024 28$484.0MTRDA, ELVN, SKYE, ARTV, DNTH
Q2 2024 28$447.1MSKYE, TRDA, ELVN, DNTH, CLDX
Q1 2024 26$446.6MELVN, TRDA, DNTH, MRUS, CLDX